Author:
Khatri Bhupendra O.,Olapo Tayo,Beals Sara,Lindman Emily,Perea Toni,Van Zealand Pamela,Metzger Ryan R
Subject
Neurology (clinical),Neurology,General Medicine
Reference19 articles.
1. Avila R., Adams B., Stevenson J., et al. PML incidence rates in US patients treated with natalizumab: Update from the TOUCH®program. Presented at: Americas Committee For Treatment and Research in Multiple Sclerosis Forum; 2022; West Palm Beach, FL, USA.
2. Biogen, 2023. Tysabri Prescribing Information. https://www.tysabri.com/content/dam/commercial/tysabri/pat/en_us/pdf/tysabri_prescribing_information.pdf.
3. Risk of natalizumab-associated progressive multifocal leukoencephalopathy;Bloomgren;N. Engl. J. Med.,2012
4. Extended interval dosing of natalizumab: a two-center, 7-year experience;Bomprezzi;Ther. Adv. Neurol. Disord.,2014
5. Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV(R) DxSelect antibody assay;Campagnolo;J. Neurovirol.,2016